Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL0006 in advanced solid tumors
NCT06247657Phase 1Recruiting
- Sponsor
- Shanghai Best-Link Bioscience
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL0006 in solid tumor (advanced stage) and hepatocellular carcinoma (HCC), sponsored by Shanghai Best-Link Bioscience. Primary endpoints: Maximum Tolerated Dose at 2 years and Recommended Phase II Dose at 2 years. Started Jan 2024; status: recruiting.
02
Drugs
BL0006
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06247657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247657.